Docosahexaenoic acid (DHA) ameliorates paraquat-induced pulmonary fibrosis in rats possibly through up-regulation of Smad 7 and SnoN

Food and Chemical Toxicology

Volumn 57, Issue , 2013, Pages 330-337

  Chen, Jingjing ^a,b   Zeng, Tao ^a   Zhao, Xiangzhong ^c   Xiea, Keqin ^a   Bi, Ye ^a   Zhong, Zhixia ^a   Zhao, Xiulan ^a  

^a SHANDONG UNIVERSITY   (China)

^b Qingdao Infectious Disease Hospital   (China)

^c QILU UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Docosahexaenoic acid; Paraquat; Pulmonary fibrosis; Smad 7; SnoN

Indexed keywords

COLLAGEN; DOCOSAHEXAENOIC ACID; HYDROXYPROLINE; MESSENGER RNA; PARAQUAT; SMAD7 PROTEIN; SNON PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC EFFECT; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; LUNG WEIGHT; LUNG WET TO DRY WEIGHT RATIO; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RESPIRATORY TRACT PARAMETERS; SUPPLEMENTATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; GENE EXPRESSION REGULATION; HYDROXYPROLINE; LUNG; MALE; NERVE TISSUE PROTEINS; PARAQUAT; PULMONARY FIBROSIS; RATS; RATS, WISTAR; SMAD7 PROTEIN; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84877595396     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.03.045     Document Type: Article

References (62)

1. Al-Turkmani M.R., Freedman S.D., Laposata M. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids 2007, 77:309-318.
2. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. Journal of Clinical Investigation 2004, 113:253-264.
3. Bartram U., Speer C.P. The role of transforming growth factor β in lung development and disease*. Chest 2004, 125:754-765.
4. Bismuth C., Garnier R., Dally S., Fournier P.E., Scherrmann J.M. Prognosis and treatment of paraquat poisoning: a review of 28 cases. Journal of Toxicology - Clinical Toxicology 1982, 19:461-474.
5. Broekelmann T.J., Limper A.H., Colby T.V., McDonald J.A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proceedings of the National Academy of Sciences 1991, 88:6642-6646.
6. Chen S.J., Yuan W., Lo S., Trojanowska M., Varga J. Interaction of Smad3 with a proximal smad-binding element of the human α2 (I) procollagen gene promoter required for transcriptional activation by TGF-β. Journal of Cellular Physiology 2000, 183:381-392.
7. Chen J., Shearer G.C., Chen Q., Healy C.L., Beyer A.J., Nareddy V.B., Gerdes A.M., Harris W.S., O'Connell T.D., Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G Signaling in cardiac fibroblastsclinical perspective. Circulation 2011, 123:584-593.
8. Chen W.Y., Lin S.Y., Pan H.C., Liao S.L., Chuang Y.H., Yen Y.J., Chen C.J. Beneficial effect of docosahexaenoic acid on cholestatic liver injury in rats. Journal of Nutritional Biochemistry 2012, 23:252-264.
9. Chen J., Zeng T., Bi Y., Zhong Z., Xie K., Zhao X. Docosahexaenoic acid (DHA) attenuated paraquat induced lung damage in mice. Inhalation Toxicology 2013, 25:9-16.
10. Christophe A., Robberecht E., De Baets F., Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Annals of Nutrition & Metabolism 1992, 36:304-312.
11. Coste T.C., Armand M., Lebacq J., Lebecque P., Wallemacq P., Leal T. An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clinical Biochemistry 2007, 40:511-520.
12. Craig-Schmidt M.C., Faircloth S.A., Teer P.A., Weete J., Wu C. The essential fatty acid deficient chicken as a model for cystic fibrosis. The American Journal of Clinical Nutrition 1986, 44:816-824.
13. Dinis-Oliveira R., Duarte J., Sánchez-Navarro A., Remiao F., Bastos M., Carvalho F. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. CRC Critical Reviews in Toxicology 2008, 38:13-71.
14. Ebisawa T., Fukuchi M., Murakami G., Chiba T., Tanaka K., Imamura T., Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. Journal of Biological Chemistry 2001, 276:12477-12480.
15. Franklin T. Therapeutic approaches to organ fibrosis. The International Journal of Biochemistry & Cell Biology 1997, 29:79-89.
16. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13995-14000.
17. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., Weed D.A., Gelrud A., Regan M.M., Laposata M., Alvarez J.G., O'Sullivan B.P. Association of cystic fibrosis with abnormalities in fatty acid metabolism. New England Journal of Medicine 2004, 350:560-569.
18. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48:959-966.
19. Hagiwara S., Iwasaka H., Matsumoto S., Noguchi T. An antisense oligonucleotide to HSP47 inhibits paraquat-induced pulmonary fibrosis in rats. Toxicology 2007, 236:199-207.
20. Harper T., Chase H., Henson J., Henson P. Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis. In vitro and in vivo effects on lung defense mechanisms. The American Review of Respiratory Disease 1982, 126:540-547.
21. Hartley D.P., Kolaja K.L., Reichard J., Petersen D.R. 4-Hydroxynonenal and malondialdehyde hepatic protein adducts in rats treated with carbon tetrachloride: immunochemical detection and lobular localization. Toxicology and Applied Pharmacology 1999, 161:23-33.
22. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone M.A., Wrana J.L. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997, 89:1165-1173.
23. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
24. Hong S.Y., Yang J.O., Lee E.Y., Lee Z.W. Effects of N-acetyl-L-cysteine and glutathione on antioxidant status of human serum and 3T3 fibroblasts. Journal of Korean Medical Science 2003, 18:649-654.
25. Hoyt D.G., Lazo J.S. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. Journal of Pharmacology and Experimental Therapeutics 1989, 249:38-43.
26. Kang J.X., Wang J., Wu L., Kang Z.B. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 2004, 427:504.
27. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., Wrana J.L. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Molecular Cell 2000, 6:1365-1375.
28. Kim H.R., Park B.K., Oh Y.M., Lee Y.S., Lee D.S., Kim H.K., Kim J.Y., Shim T.S., Lee S.D. Green tea extract inhibits paraquat-induced pulmonary fibrosis by suppression of oxidative stress and endothelin-l expression. Lung 2006, 184:287-295.
29. Kimbrough R.D. Toxic effects of the herbicide paraquat. Chest 1974, 65(Suppl.):65S-67S.
30. Lang Y.D., Chang S.F., Wang L.F., Chen C.M. Chymase mediates paraquat-induced collagen production in human lung fibroblasts. Toxicology Letters 2010, 193:19-25.
31. Luo K. Ski and SnoN: negative regulators of TGF-beta signaling. Current Opinion in Genetics & Development 2004, 14:65-70.
32. Massague J. The transforming growth factor-beta family. Annual Review of Cell Biology 1990, 6:597-641.
33. Mimoun M., Coste T.C., Lebacq J., Lebecque P., Wallemacq P., Leal T., Armand M. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. The Journal of Nutrition 2009, 139:2358-2364.
34. Nakao A., Afrakhte M., Moren A., Nakayama T., Christian J.L., Heuchel R., Itoh S., Kawabata M., Heldin N.E., Heldin C.H., ten Dijke P. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997, 389:631-635.
35. Nakao A., Imamura T., Souchelnytskyi S., Kawabata M., Ishisaki A., Oeda E., Tamaki K., Hanai J., Heldin C.H., Miyazono K. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. The EMBO Journal 1997, 16:5353-5362.
36. Nakao A., Fujii M., Matsumura R., Kumano K., Saito Y., Miyazono K., Iwamoto I. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. Journal of Clinical Investigation 1999, 104:5-11.
37. Nakao A., Okumura K., Ogawa H. Smad7: a new key player in TGF-beta-associated disease. Trends Molecular Medicine 2002, 8:361-363.
38. Nomura T., Khan M.M., Kaul S.C., Dong H.D., Wadhwa R., Colmenares C., Kohno I., Ishii S. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes & Development 1999, 13:412-423.
39. Olveira G., Olveira C., Acosta E., Espildora F., Garrido-Sanchez L., Garcia-Escobar E., Rojo-Martinez G., Gonzalo M., Soriguer F. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Archivos de Bronconeumologia 2010, 46:70-77.
40. Pardo A., Selman M. Molecular mechanisms of pulmonary fibrosis. Front Bioscience 2002, 7:d1743-1761.
41. Pearson-White S. Snol, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. Nucleic Acids Research 1993, 21:4632-4638.
42. Pearson-White S., Crittenden R. Proto-oncogene Sno expression, alternative isoforms and immediate early serum response. Nucleic Acids Research 1997, 25:2930-2937.
43. Priante, G., Musacchio, E., Valvason, C., Clari, G., Bordin, L., Sartori, L., Baggio, B., 2012. Further insights about the beneficial effects of n-3 fatty acids in the early molecular events of renal fibrosis in vitro. Journal of Nephrology, <.(Epub ahead of print). doi:10.5301/jn.5000193.
44. Pulichino A.M., Wang I.M., Caron A., Mortimer J., Auger A., Boie Y., Elias J.A., Kartono A., Xu L., Menetski J., Sayegh C.E. Identification of transforming growth factor beta1-driven genetic programs of acute lung fibrosis. American Journal of Respiratory Cell and Molecular Biology 2008, 39:324-336.
45. Rose M.S., Lock E.A., Smith L.L., Wyatt I. Paraquat accumulation: tissue and species specificity. Biochemical Pharmacology 1976, 25:419-423.
46. Roulet M., Frascarolo P., Rappaz I., Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. European Journal of Pediatrics 1997, 156:952-956.
47. Sawai T., Fujiyama J., Takahashi M., Takahashi T. The site of elevated vascular resistance in early paraquat lungs: a morphometric study of pulmonary arteries. The Tohoku Journal of Experimental Medicine 1994, 174:129.
48. Simopoulos A.P. Omega-6/Omega-3 essential fatty acids: biological effects. World Review of Nutrition and Dietetics 2009, 99:1-16.
49. Strandvik B. Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukotrienes and Essential Fatty Acids 2010, 83:121-129.
50. Stroschein S.L., Wang W., Zhou S., Zhou Q., Luo K. Negative feedback regulation of TGF-signaling by the SnoN oncoprotein. Science's STKE 1999, 286:771-774.
51. Sun Y., Zhang J., Yan Y., Chi M., Chen W., Sun P., Qin S. The protective effect of C-phycocyanin on paraquat-induced acute lung injury in rats. Environmental Toxicology and Pharmacology 2011, 32:168-174.
52. Van Biervliet S., Van Biervliet J., Robberecht E., Christophe A. Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 2005, 4:27-34.
53. Venkatesan N., Pini L., Ludwig M. Changes in Smad expression and subcellular localization in bleomycin-induced pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology 2004, 287:L1342-L1347.
54. Victory R., Saed G.M., Diamond M.P. Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts. Fertility and Sterility 2007, 88:1657-1662.
55. Xie H., Wang R., Tang X., Xiong Y., Xu R., Wu X. Paraquat-induced pulmonary fibrosis starts at an early stage of inflammation in rats. Immunotherapy 2012, 4:1809-1815.
56. Xu X., Wang W., Song Z., Ding H., Duan X., Meng H., Chong J. Imaging in detecting sites of pulmonary fibrosis induced by paraquat. World Journal of Emergency Medicine 2011, 2:45-49.
57. Yamashita M., Ando Y. A long-term follow-up of lung function in survivors of paraquat poisoning. Human and Experimental Toxicology 2000, 19:99-103.
58. Yang J., Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. Journal of the American Society of Nephrology 2002, 13:96-107.
59. Yang J., Zhang X., Li Y., Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-β1 signaling. Journal of the American Society of Nephrology 2003, 14:3167-3177.
60. Yang J., Dai C., Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. Journal of the American Society of Nephrology: JASN 2005, 16:68-78.
61. Zerin T., Kim Y.S., Hong S.Y., Song H.Y. Protective effect of methylprednisolone on paraquat-induced A549 cell cytotoxicity via induction of efflux transporter, P-glycoprotein expression. Toxicology Letters 2012, 208:101-107.
62. Zhao J., Crowe D.L., Castillo C., Wuenschell C., Chai Y., Warburton D. Smad7 is a TGF-[beta]-inducible attenuator of Smad2/3-mediated inhibition of embryonic lung morphogenesis. Mechanisms of Development 2000, 93:71-81.